3 a kallikrein-like serine protease, is one of the most abundant proteins secreted by the prostate into seminal fluid (1 ) . In the early 1990s, when the study reported in the paper presented here was initiated, serum testing for PSA was coming into widespread use as a means of testing for prostate cancer. Nevertheless, several aspects of PSA in serum remained puzzling; notably, different assays yielded up to 4-fold differences in measured serum PSA concentrations, despite standardization against PSA from seminal fluid.
Before our investigation, PSA in seminal fluid was known to occur as active monomeric peptidase (1 ), but the nature of PSA in blood remained unclear. We speculated that release of catalytic PSA into an abundance of protease inhibitors in blood could prompt PSA to form inhibitor complexes, similar to the way the digestive enzyme trypsin from the pancreas forms enzymeinhibitor complexes with ␣ 1 -antitrypsin in blood. A search for interactions between PSA and a panel of common protease inhibitors in serum allowed us to show that in vitro, catalytic PSA was able to form stable complexes with certain of these inhibitors, such as ␣ 1 -antichymotrypsin (2 ) . We hypothesized that this finding could have an important influence on immunodetection of PSA in blood. We searched for monoclonal antibodies that would enable recognition of PSA bound to ␣ 1 -antichymotrypsin, because such antibodies could be critical reagents in immunoassays that could comprehensively characterize and accurately measure the concentrations of all major forms of PSA occurring in serum in vivo. The 1991 report in Clinical Chemistry featured here resulted from these efforts.
Our collaborative work with researchers in Finland led to the generation of a set of anti-PSA monoclonal antibodies with novel binding characteristics. One clone recognized PSA isolated from seminal fluid but not PSA when it had formed the complex with ␣ 1 -antichymotrypsin, because the critical epitope became inaccessible in this complex. We also found monoclonals that independently recognized both free and complexed PSA in a roughly equimolar manner. Using these antibodies (along with a polyclonal to ␣ 1 -antichymotrypsin), we developed the first assays specific for the major PSA forms in serum, including an assay that uniquely recognized the free uncomplexed PSA form and an assay for total PSA that in an approximately equimolar manner measured the sum of free PSA and PSA in complex with ␣ 1 -antichymotrypsin.
We applied these assays to analyze sera from 64 men who were suspected to have prostate cancer. By use of gel filtration chromatography, we found the majority of PSA immunoreactivity (median, 86%) to be in complexes of the size expected for a 1:1 molar ratio PSA:␣ 1 -antichymotrypsin. Only a minority of the PSA in serum was recognized in the assay for free PSA, and this immunoreactivity was shown by gel filtration to correspond to the size expected for free PSA. The presence of these different forms of PSA in serum provided an explanation for the variability previously observed for the serum concentration of PSA; presumably, the assays that yielded low values used antibodies with inefficient recognition of complexed PSA.
This study provided the basis for later work demonstrating that both free and complexed PSA are increased in serum of men with prostate cancer, but the ratio of free to total PSA is lower in men with vs men without cancer (3, 4 ) . This ratio can help to differentiate prostate cancer from benign prostate conditions. The assays for total PSA and free PSA, with minor modifications, became commercial assays and are in widespread clinical use today.
The frequent citation of this paper is a reflection of the continued interest in assays of PSA subforms in serum as a means of improving screening for prostate cancer. Although PSA is a highly useful marker-one of the most valuable of all cancer markers-it is not perfect. PSA screening can lead to unnecessary biopsies in men with benign prostate conditions, and to overdiagnosis and overtreatment of clinically insignificant prostate cancers. A second problem is that the current standard threshold for pursuing a diagnosis of prostate cancer (4 g/L) misses some significant cancers (5 ) . To address these problems, investigators continue to test new subforms of PSA and to refine established PSA testing methods (6 ) . 
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